NO20035517D0 - Fremstilling av flumetason og dens 17-karboksyl androsten- analoge - Google Patents

Fremstilling av flumetason og dens 17-karboksyl androsten- analoge

Info

Publication number
NO20035517D0
NO20035517D0 NO20035517A NO20035517A NO20035517D0 NO 20035517 D0 NO20035517 D0 NO 20035517D0 NO 20035517 A NO20035517 A NO 20035517A NO 20035517 A NO20035517 A NO 20035517A NO 20035517 D0 NO20035517 D0 NO 20035517D0
Authority
NO
Norway
Prior art keywords
flumethasone
acetate
preparation
flumetasone
analog
Prior art date
Application number
NO20035517A
Other languages
English (en)
Other versions
NO326153B1 (no
Inventor
Ivan Villax
Zita Mendes
Original Assignee
Hovione Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20086054&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20035517(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hovione Ltd filed Critical Hovione Ltd
Publication of NO20035517D0 publication Critical patent/NO20035517D0/no
Publication of NO326153B1 publication Critical patent/NO326153B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Reduction Or Emphasis Of Bandwidth Of Signals (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Control Of Combustion (AREA)
NO20035517A 2001-06-12 2003-12-11 Fremgangsmate for fremstilling av flumetason og dens 17-karboksyl androsten-analoge NO326153B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT102628A PT102628B (pt) 2001-06-12 2001-06-12 Novo processo de preparação de flumetasona e do seu análogo 17-carboxilo androsteno
PCT/GB2002/002644 WO2002100878A1 (en) 2001-06-12 2002-06-11 Preparation of flumethasone and its 17-carboxyl androsten analogue

Publications (2)

Publication Number Publication Date
NO20035517D0 true NO20035517D0 (no) 2003-12-11
NO326153B1 NO326153B1 (no) 2008-10-06

Family

ID=20086054

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035517A NO326153B1 (no) 2001-06-12 2003-12-11 Fremgangsmate for fremstilling av flumetason og dens 17-karboksyl androsten-analoge

Country Status (19)

Country Link
US (1) US6528666B1 (no)
EP (1) EP1395603B1 (no)
JP (1) JP4095018B2 (no)
CN (1) CN1244593C (no)
AT (1) ATE460422T1 (no)
AU (1) AU2002310616B2 (no)
CA (1) CA2450661C (no)
CY (1) CY1109960T1 (no)
DE (1) DE60235625D1 (no)
DK (1) DK1395603T3 (no)
ES (1) ES2338768T3 (no)
IL (2) IL159343A0 (no)
NO (1) NO326153B1 (no)
NZ (1) NZ530536A (no)
PL (1) PL206731B1 (no)
PT (1) PT102628B (no)
RU (1) RU2260596C1 (no)
WO (1) WO2002100878A1 (no)
ZA (1) ZA200309656B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214520A (pt) 2001-11-29 2006-05-30 Taro Pharmaceuticals Usa Inc método para a preparação de corticosteróides de 6alfa-fluoro
AU2003298339A1 (en) * 2002-12-09 2004-06-30 Sicor Inc. Process for the preparation of pregnanes
EP1526139A1 (en) * 2003-10-24 2005-04-27 S.N.I.F.F. Italia S.P.A. A process for preparing highly pure androstane 17-beta-carboxylic acids and androstane 17-beta-carbothioic acid fluoromethyl esters
CN100429221C (zh) * 2005-10-31 2008-10-29 浙江仙琚制药股份有限公司 皮质激素的合成方法
CN101759761B (zh) * 2008-11-28 2012-08-08 天津金耀集团有限公司 含有6α-F的甾体化合物的制备方法
US20120178124A1 (en) 2009-01-07 2012-07-12 Mitsubishi Chemical Corporation Sterol side chain-cleaving enzyme protein and use thereof
CN101942002A (zh) * 2010-09-24 2011-01-12 岳阳环宇药业有限公司 一种甾体21位酯化物的精制工艺
ITMI20122200A1 (it) * 2012-12-20 2014-06-21 Trifarma Spa Processo per la preparazione di 6-alfa-fluoro pregnani
RU2532902C1 (ru) * 2013-07-12 2014-11-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Способ получения 11бета, 17альфа, 21-тригидрокси-16альфа-метил-9альфа-фторпрегна-1,4-диен-3,20-диона (дексаметазона) из фитостерина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499016A (en) 1958-08-04 1970-03-03 Upjohn Co 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series
US3636010A (en) 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids
NL187577C (nl) * 1978-04-05 1991-11-18 Sibla Srl 3-acetoxy-9beta,11beta-epoxy-pregna-1,3,5-trienen, werkwijze voor de bereiding daarvan en werkwijze voor de bereiding van 6alfa-halogeen-pregna-1,4-dieen-3-onen.
US4188322A (en) * 1978-04-28 1980-02-12 Blasinachim S.P.A. Process for the preparation of 6-halo-pregnanes
FR2701262B1 (fr) 1993-02-05 1995-03-24 Roussel Uclaf Nouveau procédé de préparation de stéroïdes 6 alpa, 9 alpha-difluorés et nouveaus intermédiaires.
IT1319663B1 (it) * 2000-11-17 2003-10-23 Farmabios Srl Processo per la preparazione di fluoro-steroidi.

Also Published As

Publication number Publication date
IL159343A (en) 2010-11-30
JP4095018B2 (ja) 2008-06-04
CY1109960T1 (el) 2014-09-10
EP1395603A1 (en) 2004-03-10
PT102628A (pt) 2002-12-31
US6528666B1 (en) 2003-03-04
CN1244593C (zh) 2006-03-08
PL367843A1 (en) 2005-03-07
DE60235625D1 (de) 2010-04-22
AU2002310616A2 (en) 2002-12-23
CN1531544A (zh) 2004-09-22
DK1395603T3 (da) 2010-05-10
ZA200309656B (en) 2004-06-22
IL159343A0 (en) 2004-06-01
NZ530536A (en) 2005-05-27
PL206731B1 (pl) 2010-09-30
PT102628B (pt) 2010-09-09
RU2004100309A (ru) 2005-07-10
CA2450661C (en) 2008-01-08
EP1395603B1 (en) 2010-03-10
JP2004534795A (ja) 2004-11-18
RU2260596C1 (ru) 2005-09-20
NO326153B1 (no) 2008-10-06
WO2002100878A1 (en) 2002-12-19
CA2450661A1 (en) 2002-12-19
ATE460422T1 (de) 2010-03-15
AU2002310616B2 (en) 2007-08-30
ES2338768T3 (es) 2010-05-12

Similar Documents

Publication Publication Date Title
CY1109960T1 (el) Παρασκευη φλουμεθαζονης και του αναλογου αυτης17-καρβοξυλο-ανδροστενιου
HK1082682A1 (en) Pharmaceutical composition
NO164905C (no) Fremgangsmaate for fremstilling av 16,17-acetal-pregnanderivater.
ES2181673T3 (es) Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
MY106725A (en) Method of treatment of androgen-related diseases.
NZ610068A (en) Compositions comprising povidone-iodine
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
AU4132189A (en) Process for the activation of genetically engineered, heterologous, disulphide bridge-containing eukaryotic proteins after expression in prokaryotes
TW200504078A (en) Therapeutically active compounds and their use
MXPA05010402A (es) Oxido nitrico en el tratamiento de la inflamacion.
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
HUP0203295A2 (hu) Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
SE9803761D0 (sv) Method to avoid increased iridial pigmentation during prostaglandin treatment
ECSP034470A (es) 6.alfa.,9.alfa-difluor-17.alfa.- (2-furanilcarboxilo) oxy-11.beta.-hidroxi-16.alfa.-metil-3-oxo-androst-1,4,-diene-17-acido carbotiotico s-fluormetil ester como un agente anti-inflamatorio
EP1194109A4 (en) TOPICAL FORMULATIONS CONTAINING AGENTS THAT PROMOTE SKIN PENETRATION AND THEIR USE
NO20031964D0 (no) Fremgangsmåte for fremstilling av 16,17- [(cykloheksylmetylen)bis(oksy)]-11,21-dihydroksy-pregna-1,4-dien-3,20-dion eller dets 21-isobutyratved transketalisering
HUP0203152A2 (hu) Eljárás és kompozíciók pulmonalis betegségek kezelésére
ATE462706T1 (de) 7h-pyrroloä2,3-düpyrimidinderivate sowie deren therapeutisch annehmbare salze, pharmazeutische zubereitungen, die diese enthalten, und verfahren zur herstellung des wirkstoffs
DE602008006244D1 (de) Amorphe Form von (11beta,16alpha)-9-Fluoro-11-hydroxy-16,17-Ä(1-methylethyliden)bis(oxy)Ü-21-ÄÄ4- Ä(nitrooxy)methylÜbenzoylÜoxyÜ-pregna-1,4-dien-3,20-dion
AU571073B2 (en) Pharmaceutical composition of 9a, 11b-dichcoro-16a-methl-21-oxycarbonyl dicyclohexycmethycoxy pregna-1,4-diene-3,20-dione
Henley et al. EFFECT OF IONIZING RADIATION ON AQUEOUS ETHYLENE OXYGEN SOLUTIONS
WO2004064743A3 (en) Modified retinoid compounds and their uses
WO2004033478A3 (en) Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
Moriwaki et al. Treatment of Subglottic Stenosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees